相关论文

Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes.

Abstract:CONTEXT Control of blood glucose levels, blood pressure, and cholesterol levels is proven to reduce the risk of vascular disease among individuals with diabetes mellitus; however, the current state of control of these risk factors among individuals in the United States is uncertain. OBJECTIVES To examine 1999-2000 national data on control of risk factors for vascular disease among adults with previously diagnosed diabetes and to assess trends during the past decade. DESIGN, SETTING, AND PARTICIPANTS Review of data from the Third National Health and Nutrition Examination Survey (NHANES III, conducted 1988-1994) and NHANES 1999-2000, cross-sectional surveys of a nationally representative sample of the noninstitutionalized civilian US population. Participants were adults aged 20 years and older with previously diagnosed diabetes who participated in both the interview and examination in either NHANES III (n = 1265) or NHANES 1999-2000 (n = 441). MAIN OUTCOME MEASURES Levels of glycosylated hemoglobin (HbA1c), blood pressure, and total serum cholesterol in reference to target goals. RESULTS Compared with NHANES III, participants with previously diagnosed diabetes in NHANES 1999-2000 were similar by age and sex, were less likely to be non-Hispanic white, were diagnosed at an earlier age, had a higher body mass index, and were more likely to use insulin in combination with oral agents. In NHANES 1999-2000, only 37.0% of participants achieved the target goal of HbA1c level less than 7.0% and 37.2% of participants were above the recommended "take action" HbA1c level of greater than 8.0%; these percentages did not change significantly from NHANES III (P =.11 and P =.87, respectively). Only 35.8% of participants achieved the target of systolic blood pressure (SBP) less than 130 mm Hg and diastolic blood pressure (DBP) less than 80 mm Hg, and 40.4% had hypertensive blood pressure levels (SBP > or =140 or DBP > or =90 mm Hg). These percentages did not change significantly from NHANES III (P =.10 and P =.56, respectively). Over half (51.8%) of the participants in NHANES 1999-2000 had total cholesterol levels of 200 mg/dL or greater (vs 66.1% in NHANES III; P<.001). In total, only 7.3% (95% confidence interval, 2.8%-11.9%) of adults with diabetes in NHANES 1999-2000 attained recommended goals of HbA1c level less than 7%, blood pressure less than 130/80 mm Hg, and total cholesterol level less than 200 mg/dL (5.18 mmol/L). CONCLUSION Further public health efforts are needed to control risk factors for vascular disease among individuals with diagnosed diabetes.

参考文献

[1]  S. Haffner,et al.  Effects of Diabetes and Level of Glycemia on All-Cause and Cardiovascular Mortality: The San Antonio Heart Study , 1998, Diabetes Care.

[2]  E. Barrett-Connor,et al.  Chapter 19 Heart Disease and Diabetes , 2022 .

[3]  Terje R Pedersen,et al.  Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.

[4]  H. King,et al.  Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections , 1998, Diabetes Care.

[5]  R. Holman,et al.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.

[6]  W. Newton,et al.  Tight blood pressure control in type 2 diabetes. , 1998, The Journal of family practice.

[7]  The National Diabetes Education Program: Changing the Way Diabetes Is Treated , 1999, Annals of Internal Medicine.

[8]  K. Flegal,et al.  Racial and ethnic differences in glycemic control of adults with type 2 diabetes. , 1999, Diabetes care.

[9]  Daniel W. Jones,et al.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. , 2003, JAMA.

[10]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[11]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[12]  G. Duvel The study group. , 1980 .

[13]  Michael M Engelgau,et al.  Elevated blood pressure among U.S. adults with diabetes, 1988-1994. , 2002, American journal of preventive medicine.

[14]  Standards of Medical Care for Patients With Diabetes Mellitus , 1991, Diabetes Care.

[15]  D. Snider,et al.  Prevalence of diabetes and impaired fasting glucose in adults--United States, 1999-2000. , 2003, MMWR. Morbidity and mortality weekly report.

[16]  Adrienne Jones The National Nursing Home Survey: 1999 summary. , 2002, Vital and health statistics. Series 13, Data from the National Health Survey.

[17]  Matthew D. Davis,et al.  Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. , 2002, JAMA.

[18]  F. Vinicor,et al.  The National Diabetes Education Program, Changing the Way Diabetes Is Treated Comprehensive diabetes care , 2001 .

[19]  A. Mokdad,et al.  Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. , 2003, JAMA.

[20]  Jeannine S. Schiller,et al.  Summary health statistics for U.S. adults: National Health Interview Survey, 2000. , 2003, Vital and health statistics. Series 10, Data from the National Health Survey.

[21]  T. Lennie,et al.  Perceived Adherence to Prescribed or Recommended Standards of Care Among Adults With Diabetes , 2002, The Diabetes educator.

[22]  James C. Robinson,et al.  As good as it gets? Chronic care management in nine leading US physician organisations , 2002, BMJ : British Medical Journal.

[23]  C. Johnston,et al.  Optimizing treatment of hypertension in patients with diabetes. , 2000, Journal of the American Medical Association (JAMA).

[24]  S. Tesfaye Neuropathy in diabetes , 2006 .

[25]  K. Flegal,et al.  Prevalence and trends in obesity among US adults, 1999-2000. , 2002, JAMA.

[26]  岩崎 二郎,et al.  National Cholesterol Education Program (NCEP) 第2次指針による高脂血症の検討 , 1995 .

[27]  E. Steinberg,et al.  Improving the quality of care--can we practice what we preach? , 2003, The New England journal of medicine.

[28]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[29]  Y. Li,et al.  [Trends in prevalence, awareness, treatment and control of hypertension in middle-aged Chinese population]. , 2004, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[30]  R. Klein Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes , 1995, Diabetes Care.

[31]  M. Laakso,et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.

[32]  S. Haffner Management of Dyslipidemia in Adults With Diabetes , 1998, Diabetes Care.

[33]  L. Egede,et al.  Modifiable cardiovascular risk factors in adults with diabetes: prevalence and missed opportunities for physician counseling. , 2002, Archives of internal medicine.

[34]  E. Gunter,et al.  Laboratory procedures used for the third National Health and Nutrition Examination Survey (NHANES III), 1988-1994 , 1996 .

[35]  Ihab Hajjar,et al.  Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. , 2003, JAMA.

[36]  D. O'leary,et al.  Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. , 2003, The New England journal of medicine.

[37]  M. Engelgau,et al.  A Diabetes Report Card for the United States: Quality of Care in the 1990s , 2002, Annals of Internal Medicine.

[38]  C. Gabrel,et al.  The National Nursing Home Survey: 1999 summary. , 2002, Vital and health statistics. Series 13, Data from the National Health Survey.

[39]  W. O’Neill,et al.  Treatment of cardiac risk factors in diabetic patients: How well do we follow the guidelines? , 2001, American heart journal.

[40]  S. Grundy,et al.  Prevention Conference VI: Diabetes and Cardiovascular Disease: Executive Summary Conference Proceeding for Healthcare Professionals From a Special Writing Group of the American Heart Association , 2002, Circulation.

[41]  M. Szklo,et al.  Epidemiology: Beyond the Basics , 1999 .

[42]  Anke Richter,et al.  Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. , 2002, JAMA.

[43]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[44]  S. Greenfield,et al.  The Diabetes Quality Improvement Project: moving science into health policy to gain an edge on the diabetes epidemic. , 2001, Diabetes care.

[45]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[46]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .

引用
Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: pathophysiological insights.
Antioxidants & redox signaling
2007
The burgeoning public health impact of diabetes: the role of the ophthalmologist.
Archives of ophthalmology
2011
Heart disease and stroke statistics--2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.
Circulation
2008
Cardiovascular Outcomes in Framingham Participants With Diabetes: The Importance of Blood Pressure
Hypertension
2011
Glucokinase activators in diabetes management
Expert opinion on investigational drugs
2008
Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial
Diabetes, obesity & metabolism
2020
Meeting American Diabetes Association diabetes management targets: trends in Mauritius
Diabetic medicine : a journal of the British Diabetic Association
2017
Rosiglitazone plus metformin is effective and well tolerated in clinical practice: results from large observational studies in people with type 2 diabetes
International journal of clinical practice
2005
Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus
Obesity
2020
ASH Position Paper: Treatment of Hypertension in Patients With Diabetes—An Update
Journal of clinical hypertension
2008
Linhas de Fuga no Processo Artístico com a Tecnologia Digital * (Digital Technology and Art Crossings Generating Fugue Lines on Creation Processes)
2003
Closing Statement: What Have We Said About Computation?
Comput. J.
2012
Pulmonary Delivery as a Route for Insulin
2009
Bridging the knowledge—action gap in diabetes: information technologies, physician incentives and consumer incentives converge
Chronic illness
2006
Patient-Centered Medical Home and Diabetes
Diabetes Care
2011
Current challenges in diabetes management.
Clinical cornerstone
2005
Review of the Effect of Dairy Products on Non-Lipid Risk Factors for Cardiovascular Disease
Journal of the American College of Nutrition
2008
Metabolic Surgery for Type 2 Diabetes: Changing the Landscape of Diabetes Care
Diabetes Care
2016
Approach for a Clinically Useful Comprehensive Classification of Vascular and Neural Aspects of Diabetic Retinal Disease
Investigative ophthalmology & visual science
2018
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Diabetes Care
2007